Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CM
Chemomab Therapeutics Ltd. American Depositary Share
CMMB
Mkt Cap
$9.3M
Volume
9.04K
Next Earnings
October 22nd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CM
CMMB
CM
Chemomab Therapeutics Ltd. American Depositary Share
CMMB
News
·
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Mkt Cap
$9.3M
Volume
9.04K
Next Earnings
October 22nd
Chart
Financials
Earnings
News
About
Insider
Filings
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported Q1 2026 financial results showing a net loss of $1.8 million and cash position of $8.0 million (runway through Q1 2027). The company presented new clinical data at major medical conferences demonstrating nebokitug's disease-modifying potential in primary sclerosing cholangitis (PSC) and potential benefits for PSC patients with co-existing inflammatory bowel disease (IBD). Multiple proteomic and gene expression analyses showed dose-dependent reductions in fibrosis and inflammatory biomarkers. The company continues advancing strategic partnership discussions for nebokitug.
GlobeNewswire Inc. · May 14, 2026
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Chemomab Therapeutics reported positive 2025 results highlighted by successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), establishing a clear pathway to potential regulatory approval based on a single Phase 3 trial. The company's Phase 2 SPRING trial data showed nebokitug was safe and well-tolerated with improvements in inflammation and fibrosis biomarkers. Cash position of $10.4 million is expected to fund operations through Q1 2027, with R&D expenses declining to $5.8 million for 2025 as the Phase 2 trial completed.
GlobeNewswire Inc. · Mar 19, 2026
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Chemomab's CM-101 demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic activity in a Phase 2 trial for primary sclerosing cholangitis, a rare liver disease. The data supports further clinical development of CM-101 for this condition.
GlobeNewswire Inc. · Nov 19, 2024
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics reported positive Phase 2 results for its lead drug candidate CM-101 in primary sclerosing cholangitis, demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company plans to advance CM-101 to a Phase 3 trial and is in discussions with potential partners.
GlobeNewswire Inc. · Aug 21, 2024
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics, a clinical-stage biotechnology company, announced it will report its Q2 2024 financial results and provide a business update on August 21, 2024. The company is developing a monoclonal antibody, CM-101, to treat various fibro-inflammatory diseases.
GlobeNewswire Inc. · Aug 12, 2024
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research · Jun 27, 2024
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference
GlobeNewswire Inc. · Jun 6, 2024
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of the Liver.
GlobeNewswire Inc. · May 17, 2024
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks Investment Research · May 10, 2024
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.
GlobeNewswire Inc. · Apr 2, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CM
CMMB
Chemomab Therapeutics Ltd. American Depositary Share
Buy
Sell
Market
Limit
Soon
CMMB
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CMMB yet.
Related Tickers
Earnings